pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·3h ago·1 min read
save

Webinar Explores Manufacturing Risks and Partner Strategies for the Next Five Years

Sep 17, 2026·read at BioSpace ↗Neutral

The webinar titled "Manufacturing in Turbulent Times" is scheduled for September 17, 2026 and is designed to help biopharma sponsors understand the manufacturing challenges that lie ahead.

It notes that capacity constraints, geopolitical pressure, tighter regulatory scrutiny and fragmented technology are converging to create a volatile environment for drug production.

Sponsors and contract manufacturing organizations are encouraged to strengthen partnerships, and the session will offer a practical framework and checklist for selecting CDMOs or CMOs that can endure these pressures.

Attendees will learn how to avoid common pitfalls such as process‑transfer gaps and compliance blind spots, and will gain insight into the traits of future‑ready manufacturing partners.

source

This writeup was produced by pharmadog from original reporting by BioSpace.

Original headline: “Webinar: Manufacturing in Turbulent Times”

read at BioSpace ↗
705 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
University of Pennsylvania
topics
Gene Therapy (AAV)6CRO/CDMO4CAR-TCell TherapyImmunologyMonoclonal Antibody

related stories

  • 1d agoSionna says good-bye to 46% of staffers, including execBioSpace
  • Sep 3The hidden scale-out problem behind CAR-T’s growthBioPharma Dive
  • Aug 14After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?Fierce Biotech
  • Jul 24Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effectsFierce Biotech
  • Dec 23Fierce Biotech Layoff Tracker 2026: Sionna halves staff; Merck trims more NJ jobsFierce Biotech